Pre-exposure prophylaxis (PrEP) is safe for pregnant women to use, according to new research presented at the HIV Research for Prevention (HIVR4P2018) conference in Madrid, Spain.
The benefits of pre-pregnancy HIV treatment initiation for mothers-to-be; HIV diagnoses rise among young U.S. MSM; cost effectiveness of PrEP for heterosexual women; methotrexate and arterial function.
Three new trials of HIV prevention drugs seek to answer directly a question that researchers inside and outside the field of HIV have explicitly avoided for years: How do drugs work -- and are they safe -- in pregnant and breastfeeding women?
The effect of specific regimens on some birth-related events; obstacles to PrEP among U.S. women; improving mortality and treatment success for HIV-positive people who inject drugs; kidney disease and “old” tenofovir.
New information was presented at the 2018 International AIDS Conference in Amsterdam about babies born with neural tube defects to women with HIV who started a regimen with dolutegravir (Tivicay, DTG) and then later got pregnant.
The risk of transmitting HIV through the breastmilk of virally suppressed women in high-income countries is not known.
"It is hard to imagine how in 2018 we could be in this situation where women with HIV are being so woefully underserved," Polly Clayden writes.
Lower CD4, higher viral load in the U.S. South; HIV testing among U.S. heterosexuals; heightened seroconversion risk around childbirth; predicting success for long-acting, injectable PrEP.
A recent case study illustrates the complexity of managing women in early stages of pregnancy presenting on a dolutegravir-based regimen, and the need for careful consideration when responding to new data.
The manufacturer of darunavir/cobicistat (Prezcobix) has issued a Dear Doctor letter warning about use of the drug during pregnancy due to significantly reduced plasma levels of the drug during the second and third trimesters.